✦ LIBER ✦

64 SAFETY OF THE HCV PROTEASE INHIBITOR TMC435350 IN HEALTHY VOLUNTEERS AND SAFETY AND ACTIVITY IN CHRONIC HEPATITIS C INFECTED INDIVIDUALS: A PHASE I STUDY

✍ Scribed by H. Reesink; R. Verloes; K. Abou Farha; A. Van Vliet; C. Weegink; G. van 't Klooster; F. Aharchi; K. Marien; P. Van Remoortere; H. de Kock; F. Broeckaert; G. Fanning; P. Meyvisch; E. Van Beirendonck; K. Simmen

Book ID: 117375990
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 72 KB
Volume: 48
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(08)60066-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

940 SAFETY, TOLERABILITY AND PHARMACOKIN

940 SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR VCH-222 FOLLOWING SINGLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS AND ANTIVIRAL ACTIVITY IN HCV-INFECTED INDIVIDUALS

✍ C. Cooper; R. Larouche; B. Bourgault; N. Chauret; L. Proulx 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

941 JTK-652 IS A NOVEL HCV ENTRY INHIBIT

941 JTK-652 IS A NOVEL HCV ENTRY INHIBITOR: RESULTS OF A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY IN CHRONIC HEPATITIS C PATIENTS

✍ J. de Bruijne; J. Bergmann; C. Weegink; K. van Nieuwkerk; R. de Knegt; J. van de 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Safety and Antiviral Activity of the HCV

Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study

✍ Sulkowski, M. S.; Kang, M.; Matining, R.; Wyles, D.; Johnson, V. A.; Morse, G. D 📂 Article 📅 2013 🏛 University of Chicago Press 🌐 English ⚖ 338 KB

Characterization of vaniprevir, a hepati

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

✍ Lawitz, Eric; Sulkowski, Mark; Jacobson, Ira; Kraft, Walter K.; Maliakkal, Bened 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 367 KB

854 RESULTS OF A SAFETY, TOLERABILITY AN

854 RESULTS OF A SAFETY, TOLERABILITY AND PHARMACOKINETIC PHASE I STUDY OF VCH-916, A NOVEL POLYMERASE INHIBITOR FOR HCV, FOLLOWING SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS

✍ L. Proulx; B. Bourgault; N. Chauret; R. Larouche; M. Tanguay; R. Thibert 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

W1011 Phase I Study to Evaluate the Safe

W1011 Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Silymarin (SM) Following Chronic Dosing in Patients with Chronic Hepatitis C (HCV)

✍ Schrieber, Sarah J.; Soule, Tedi A.; Wen, Zhiming; Wahed, Abdus S.; Smith, Phili 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 132 KB